'says Stephan Grupp, director of cancer immunotherapy at the Children’s Hospital of Philadelphia, who collaborates with Novartis.' I don't know if I would trus

'says Stephan Grupp, director of cancer immunotherapy at the Children’s Hospital of Philadelphia, who collaborates with Novartis.' I don't know if I would trust the opinion of somebody that 'collaborates' with one of the companies that has already lost millions trying a different approach and has the most to lose if this actually works. It even points this out earlier in the article - 'The ready-made approach could pose a challenge to companies including Juno Therapeutics and Novartis, each of which has spent tens of millions of dollars pioneering treatments that require collecting a patient’s own blood cells, engineering them, and then re-infusing them.'